Harmony Biosciences Q3 2024 10-Q Filing
Ticker: HRMY · Form: 10-Q · Filed: Oct 29, 2024 · CIK: 1802665
| Field | Detail |
|---|---|
| Company | Harmony Biosciences Holdings, INC. (HRMY) |
| Form Type | 10-Q |
| Filed Date | Oct 29, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
TL;DR
Harmony Biosciences filed its Q3 2024 10-Q. Financials and ops update.
AI Summary
Harmony Biosciences Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business operations. Key financial figures and operational details are presented in this quarterly report.
Why It Matters
This filing provides investors with an update on Harmony Biosciences' financial health and operational performance for the third quarter of 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — Quarterly reports can reveal significant financial shifts or operational challenges that impact stock value.
Key Players & Entities
- Harmony Biosciences Holdings, Inc. (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- 20241029 (date) — Date of filing
- 0001802665 (company) — Central Index Key for Harmony Biosciences Holdings, Inc.
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on October 29, 2024.
What is the Central Index Key (CIK) for Harmony Biosciences Holdings, Inc.?
The CIK for Harmony Biosciences Holdings, Inc. is 0001802665.
What is the Standard Industrial Classification (SIC) code for Harmony Biosciences Holdings, Inc.?
The SIC code for Harmony Biosciences Holdings, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the fiscal year end for Harmony Biosciences Holdings, Inc.?
The fiscal year end for Harmony Biosciences Holdings, Inc. is December 31.
Filing Stats: 4,380 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-10-29 08:00:42
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 value per share HRMY The Nasdaq Sto
Filing Documents
- hrmy-20240930x10q.htm (10-Q) — 1774KB
- hrmy-20240930xex31d1.htm (EX-31.1) — 16KB
- hrmy-20240930xex31d2.htm (EX-31.2) — 16KB
- hrmy-20240930xex32d1.htm (EX-32.1) — 10KB
- hrmy-20240930xex32d2.htm (EX-32.2) — 9KB
- 0001558370-24-013803.txt ( ) — 8750KB
- hrmy-20240930.xsd (EX-101.SCH) — 68KB
- hrmy-20240930_cal.xml (EX-101.CAL) — 83KB
- hrmy-20240930_def.xml (EX-101.DEF) — 189KB
- hrmy-20240930_lab.xml (EX-101.LAB) — 557KB
- hrmy-20240930_pre.xml (EX-101.PRE) — 396KB
- hrmy-20240930x10q_htm.xml (XML) — 1597KB
Financial Information
Part I. Financial Information 3
Financial Statements
Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) 5 Condensed Consolidated Statements of Cash Flows (Unaudited) 6 Notes to Condensed Consolidated Financial Statements (Unaudited) 7
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 26
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 41
Controls and Procedures
Item 4. Controls and Procedures 41
Other Information
Part II. Other Information 42
Legal Proceedings
Item 1. Legal Proceedings 42
Risk Factors
Item 1A. Risk Factors 42
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 42
Defaults upon Senior Securities
Item 3. Defaults upon Senior Securities 42
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 42
Other Information
Item 5. Other Information 43
Exhibits
Item 6. Exhibits 44
Signatures
Signatures 45 2 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) September 30, December 31, 2024 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 387,367 $ 311,660 Investments, short-term 23,109 41,800 Trade receivables, net 81,502 74,140 Inventory, net 6,915 5,363 Prepaid expenses 16,057 12,570 Other current assets 7,455 5,537 Total current assets 522,405 451,070 NONCURRENT ASSETS: Property and equipment, net 750 371 Restricted cash 270 270 Investments, long-term 94,222 72,169 Intangible assets, net 119,225 137,108 Deferred tax asset 185,016 144,162 Other noncurrent assets 6,247 6,298 Total noncurrent assets 405,730 360,378 TOTAL ASSETS $ 928,135 $ 811,448 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables $ 10,532 $ 17,730 Accrued compensation 14,224 23,747 Accrued expenses 109,673 99,494 Current portion of long-term debt 15,000 15,000 Other current liabilities 11,850 7,810 Total current liabilities 161,279 163,781 NONCURRENT LIABILITIES: Long-term debt, net 167,847 178,566 Other noncurrent liabilities 2,205 2,109 Total noncurrent liabilities 170,052 180,675 TOTAL LIABILITIES 331,331 344,456 COMMITMENTS AND CONTINGENCIES (Note 13) STOCKHOLDERS' EQUITY: Common stock—$ 0.00001 par value; 500,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 57,030,897 and 56,769,081 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 1 1 Additional paid in capital 643,563 610,266 Accumulated other comprehensive (loss) income 499 2 Accumulated deficit ( 47,259 ) ( 143,277 ) TOTAL STOCKHOLDERS' EQUITY 596,804 466,992 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 928,135 $ 811,448 The accompanying n